Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2018

Study Completion Date

July 1, 2019

Conditions
Crohn's DiseaseIBD
Interventions
DRUG

Anti-TNF

All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.

DRUG

Anti-TNF

All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.

DRUG

Steroids

All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.

Trial Locations (4)

21201

Mercy Medical Center, Baltimore

University of Maryland School of Medicine, Baltimore

Unknown

Penn State Hershey Medical Center, Hershey

Vanderbilt University, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vanderbilt University

OTHER

collaborator

Milton S. Hershey Medical Center

OTHER

collaborator

Mercy Medical Center

OTHER

lead

University of Maryland, Baltimore

OTHER